Haloperidol
Based on 22 publication(s) in Google Scholar
Haloperidol is a potent dopamine D2 receptor antagonist, widely used as an antipsychotic agent. Haloperidol can be used in the study of schizophrenia, tics in Tourette syndrome, mania in bipolar disorder, delirium, agitation, acute psychosis, and hallucinations from alcohol withdrawal.
For research use only. We do not sell to patients.
- Purity: 99.69%
- CAS No.: 52-86-8
- Formula: C21H23ClFNO2
- Molecular Weight:375.86
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
Publications Citing Use of MedChemExpress (MCE) Haloperidol
More- Cell. 2023 Nov 22;186(24):5347-5362.e24. [Abstract]
- Adv Sci (Weinh). 2025 Sep;12(33):e02276. [Abstract]
- Environ Sci Technol. 2023 Sep 26;57(38):14162-14172. [Abstract]
- Acta Biomater. 2026 Jun:216:333-347. [Abstract]
- Phytomedicine. 2025 Jun:141:156707. [Abstract]
- Br J Pharmacol. 2021 Sep;178(17):3570-3586. [Abstract]
- Oncogenesis. 2025 Aug 21;14(1):31. [Abstract]
- EMBO Rep. 2022 Feb 3;23(3):e53191. [Abstract]
- J Ethnopharmacol. 2021 Jun 12:273:113994. [Abstract]
- Eur J Pharmacol. 2023 Dec 15:961:176174. [Abstract]
- Eur J Pharmacol. 2023 May 5:946:175647. [Abstract]
- Cell Rep Methods. 2023 Oct 23;3(10):100599. [Abstract]
- ACS Omega. 2025 Oct 17;10(42):50208-50217. [Abstract]
- ACS Omega. 2020 Nov 15;5(46):29935-29942. [Abstract]
- PLoS Negl Trop Dis. 2019 Aug 20;13(8):e0007681. [Abstract]
- BMC Endocr Disord. 2021 Nov 23;21(1):235. [Abstract]
- Clin Exp Pharmacol Physiol. 2021 Mar;48(3):370-380. [Abstract]
- Behav Brain Res. 2022 Mar 26:422:113759. [Abstract]
- Eur J Integr Med. 2021, 101322.
- Clin Tradit Med Pharmacol. 2026 Jan 14.
- University of South Carolina. 2025.
- University of Zurich. 2025.
-
WB
-
WB
-
Cell Proliferation/Viability Assay
-
Cell Imaging/Staining
-
WB
All Dopamine Receptor Isoforms
More
Biological Activity
|
D2 Receptor |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| 5637 | IC50 |
>20 μM
Compound: Haloperidol
|
Cytotoxicity against human 5637 cells after 96 hrs by crystal violet staining
Cytotoxicity against human 5637 cells after 96 hrs by crystal violet staining
|
[PMID: 19243173] |
| 5637 | IC50 |
2.3 μM
Compound: Haloperidol
|
Growth inhibition of human 5637 cells incubated for 96 hrs by crystal violet assay
Growth inhibition of human 5637 cells incubated for 96 hrs by crystal violet assay
|
[PMID: 27156565] |
| A-427 | IC50 |
10 μM
Compound: Haloperidol
|
Growth inhibition of human A427 cells after 96 hrs
Growth inhibition of human A427 cells after 96 hrs
|
[PMID: 17967001] |
| A-427 | IC50 |
10 μM
Compound: Haloperidol
|
Cytotoxicity against human A427 cells after 96 hrs by crystal violet staining
Cytotoxicity against human A427 cells after 96 hrs by crystal violet staining
|
[PMID: 19243173] |
| A-427 | IC50 |
9.6 μM
Compound: Haloperidol
|
Growth inhibition of human A427 cells incubated for 96 hrs by crystal violet assay
Growth inhibition of human A427 cells incubated for 96 hrs by crystal violet assay
|
[PMID: 27156565] |
| CHO | IC50 |
32 nM
Compound: haloperidol
|
Inhibition of K+ channel activity in CHO cells expressing HERG Kv11.1
Inhibition of K+ channel activity in CHO cells expressing HERG Kv11.1
|
[PMID: 12729675] |
| CHO | IC50 |
1.1 μM
Compound: Haloperidol
|
Inhibition of human ERG expressed in CHO cells after 30 mins by Rb+ flux assay
Inhibition of human ERG expressed in CHO cells after 30 mins by Rb+ flux assay
|
[PMID: 22677319] |
| CHO | IC50 |
1.3 μM
Compound: haloperidol
|
Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits
Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits
|
[PMID: 23812503] |
| CHO | IC50 |
4.8 nM
Compound: Haloperidol
|
Binding affinity to rat Dopamine receptor D2 expressed in CHO cells was determined using [125 I ] iodosulpride as radioligand
Binding affinity to rat Dopamine receptor D2 expressed in CHO cells was determined using [125 I ] iodosulpride as radioligand
|
[PMID: 8759642] |
| CHO | IC50 |
0.006 μM
Compound: haloperidol
|
Inhibitory concentration against human Dopamine receptor D4.2 in CHO cells
Inhibitory concentration against human Dopamine receptor D4.2 in CHO cells
|
[PMID: 8831770] |
| CHO-hD3 | IC50 |
8.8 nM
Compound: Haloperidol
|
Compound was tested for stimulation of mitogenesis in CHO.hD3 cells in a dose dependent manner
Compound was tested for stimulation of mitogenesis in CHO.hD3 cells in a dose dependent manner
|
[PMID: 9873609] |
| CHO-K1 | IC50 |
5500 nM
Compound: 5
|
Inhibition of binding of 1.0 nM [3H]pirenzepine to cloned human Muscarinic acetylcholine receptor M1 expressed in membranes from CHO-K1 cells
Inhibition of binding of 1.0 nM [3H]pirenzepine to cloned human Muscarinic acetylcholine receptor M1 expressed in membranes from CHO-K1 cells
|
[PMID: 10377229] |
| CHO-K1 | IC50 |
0.16 nM
Compound: Haloperidol
|
Antagonist activity against human D2LR expressed in CHOK1 cells assessed as inhibition of pergolide-induced beta-arrestin translocation by beta-galactosidase based beta-arrestin recruitment assay
Antagonist activity against human D2LR expressed in CHOK1 cells assessed as inhibition of pergolide-induced beta-arrestin translocation by beta-galactosidase based beta-arrestin recruitment assay
|
[PMID: 25126833] |
| CHO-K1 | IC50 |
5500 nM
Compound: haloperidol
|
Inhibitory binding of [3H]pirenzepine to human Muscarinic acetylcholine receptor M1 in membranes from CHO-K1 cells
Inhibitory binding of [3H]pirenzepine to human Muscarinic acetylcholine receptor M1 in membranes from CHO-K1 cells
|
[PMID: 9406603] |
| DAN-G | IC50 |
>20 μM
Compound: Haloperidol
|
Growth inhibition of human DAN-G cells incubated for 96 hrs by crystal violet assay
Growth inhibition of human DAN-G cells incubated for 96 hrs by crystal violet assay
|
[PMID: 27156565] |
| HEK293 | EC50 |
>10000 nM
Compound: Haloperidol
|
Agonist activity was calculated in calcium flux assay using HEK293 cells co-transfected with human Dopamine receptor D4.4 and Galphaqo5
Agonist activity was calculated in calcium flux assay using HEK293 cells co-transfected with human Dopamine receptor D4.4 and Galphaqo5
|
[PMID: 15380206] |
| HEK293 | IC50 |
141.9 μM
Compound: haloperidole
|
Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells by confocal microscopy
Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells by confocal microscopy
|
[PMID: 18788725] |
| HEK293 | IC50 |
0.23 μM
Compound: haloperidol
|
Inhibition of human ERG expressed in HEK293 cells coexpressing Kir2.3 after 30 mins by FluxOR based FLIPR assay
Inhibition of human ERG expressed in HEK293 cells coexpressing Kir2.3 after 30 mins by FluxOR based FLIPR assay
|
[PMID: 22694270] |
| HEK293 | IC50 |
0.55 μM
Compound: Haloperidol
|
Antagonist activity at dopamine D2 receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of [35S]GTPgammaS binding by scintillation proximity assay
Antagonist activity at dopamine D2 receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of [35S]GTPgammaS binding by scintillation proximity assay
|
[PMID: 23332346] |
| HEK293 | IC50 |
0.7 nM
Compound: Haloperidol
|
Antagonist activity at human dopamine D2 short receptor transiently expressed in HEK293 cells assessed as inhibition of beta-arrestin recruitment after 6 hrs by chemiluminescence assay
Antagonist activity at human dopamine D2 short receptor transiently expressed in HEK293 cells assessed as inhibition of beta-arrestin recruitment after 6 hrs by chemiluminescence assay
|
[PMID: 24831693] |
| HEK293 | IC50 |
1.16 μM
Compound: Haloperidol
|
Inhibition of human ERG expressed in HEK293 cells measured after 30 mins by FluxOR dye based FLIPR TETRA assay
Inhibition of human ERG expressed in HEK293 cells measured after 30 mins by FluxOR dye based FLIPR TETRA assay
|
[PMID: 32392053] |
| HL-60 | IC50 |
>20 μM
Compound: Haloperidol
|
Growth inhibition of human HL60 cells incubated for 48 hrs by MTT assay
Growth inhibition of human HL60 cells incubated for 48 hrs by MTT assay
|
[PMID: 27156565] |
| Jurkat | IC50 |
230 nM
Compound: haloperidol
|
Displacement of [3H](+)-pentazocine from sigma 1 opioid receptor in human Jurkat cells by scintillation counting
Displacement of [3H](+)-pentazocine from sigma 1 opioid receptor in human Jurkat cells by scintillation counting
|
[PMID: 19875205] |
| Jurkat | IC50 |
0.021 μM
Compound: haloperidol
|
Displacement of [3H]Haloperidol from sigma 1 receptor in human jurkat cells after 4 hrs
Displacement of [3H]Haloperidol from sigma 1 receptor in human jurkat cells after 4 hrs
|
[PMID: 23403082] |
| Jurkat | IC50 |
1.7 x 10-8 M
Compound: Haloperidol
|
Displacement of [3H]DTG from sigma receptor in human jurkat cells
Displacement of [3H]DTG from sigma receptor in human jurkat cells
|
[PMID: 26988801] |
| Jurkat | IC50 |
1.7 x 10-8 M
Compound: Haloperidol
|
Displacement of [3H]DTG from sigma receptor in human Jurkat cells measured after 120 mins by scintillation counting method
Displacement of [3H]DTG from sigma receptor in human Jurkat cells measured after 120 mins by scintillation counting method
|
[PMID: 27876250] |
| Jurkat | IC50 |
1.7 x 10-2 μM
Compound: Haloperidol
|
Displacement of [3H]DTG from sigma receptor in human Jurkat cells measured after 120 mins by scintillation counting method
Displacement of [3H]DTG from sigma receptor in human Jurkat cells measured after 120 mins by scintillation counting method
|
[PMID: 27876250] |
| LCLC-103H cell line | IC50 |
>20 μM
Compound: Haloperidol
|
Cytotoxicity against human LCLC-103H cells after 96 hrs by crystal violet staining
Cytotoxicity against human LCLC-103H cells after 96 hrs by crystal violet staining
|
[PMID: 19243173] |
| LCLC-103H cell line | IC50 |
10.9 μM
Compound: Haloperidol
|
Growth inhibition of human LCLC-103H cells incubated for 96 hrs by crystal violet assay
Growth inhibition of human LCLC-103H cells incubated for 96 hrs by crystal violet assay
|
[PMID: 27156565] |
| MCF7 | IC50 |
24.9 μM
Compound: Haloperidol
|
Growth inhibition of human MCF7 cells after 96 hrs
Growth inhibition of human MCF7 cells after 96 hrs
|
[PMID: 17967001] |
| MCF7 | IC50 |
>20 μM
Compound: Haloperidol
|
Cytotoxicity against human MCF7 cells after 96 hrs by crystal violet staining
Cytotoxicity against human MCF7 cells after 96 hrs by crystal violet staining
|
[PMID: 19243173] |
| MCF7 | IC50 |
>20 μM
Compound: Haloperidol
|
Growth inhibition of human MCF7 cells incubated for 96 hrs by crystal violet assay
Growth inhibition of human MCF7 cells incubated for 96 hrs by crystal violet assay
|
[PMID: 27156565] |
| MCF7 | IC50 |
20.17 μM
Compound: Haloperidol
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 31042618] |
| MCF7 | IC50 |
68 μM
Compound: Halo
|
Cytotoxicity against ER/PR-positive HER2-negative human MCF7 cells harbouring p53 R175H mutant assessed as inhibition of cell growth incubated for 48 hrs by resazurin dye based assay
Cytotoxicity against ER/PR-positive HER2-negative human MCF7 cells harbouring p53 R175H mutant assessed as inhibition of cell growth incubated for 48 hrs by resazurin dye based assay
|
[PMID: 35724925] |
| RT-4 | IC50 |
>20 μM
Compound: Haloperidol
|
Cytotoxicity against human RT4 cells after 96 hrs by crystal violet staining
Cytotoxicity against human RT4 cells after 96 hrs by crystal violet staining
|
[PMID: 19243173] |
| RT-4 | IC50 |
16 μM
Compound: Haloperidol
|
Growth inhibition of human RT4 cells incubated for 96 hrs by crystal violet assay
Growth inhibition of human RT4 cells incubated for 96 hrs by crystal violet assay
|
[PMID: 27156565] |
| ScN2a | EC50 |
>10 μM
Compound: Haloperidol
|
Half maximal inhibition of Prion protein PrPsc formation was assayed in ScN2a cells
Half maximal inhibition of Prion protein PrPsc formation was assayed in ScN2a cells
|
[PMID: 12904059] |
| SK-BR-3 | IC50 |
131 μM
Compound: Halo
|
Cytotoxicity against ER/PR-negative HER2-positive human SK-BR-3 cells harbouring wild type p53 assessed as inhibition of cell growth incubated for 48 hrs by resazurin dye based assay
Cytotoxicity against ER/PR-negative HER2-positive human SK-BR-3 cells harbouring wild type p53 assessed as inhibition of cell growth incubated for 48 hrs by resazurin dye based assay
|
[PMID: 35724925] |
| U2OS | IC50 |
0.06 nM
Compound: Haloperidol
|
Antagonist activity against D3R in human U2OS cells assessed as inhibition of (+)-PD128907-induced beta-arrestin translocation by beta-galactosidase based beta-arrestin recruitment assay
Antagonist activity against D3R in human U2OS cells assessed as inhibition of (+)-PD128907-induced beta-arrestin translocation by beta-galactosidase based beta-arrestin recruitment assay
|
[PMID: 25126833] |
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.
Haloperidol can be used to create tardive dyskinesia models. In rats, the oral half-life of Haloperidol is 5.9 hours, with a Tmax of 0.9 hours, a Cmax of 6.8 ng/mL, and an oral bioavailability of 23.0%. When administered intravenously, the AUC0-∞ of Haloperidol is 188.4 ng·h/mL, and the t1/2 is 2.9 hours[3].
Administration: 1 mg/KG • i.p. • daily for 31 days
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 52-86-8
-
Appearance Solid
-
Molecular Weight 375.86
-
Formula C21H23ClFNO2
-
Color White to off-white
-
SMILES
ClC(C=C1)=CC=C1C2(O)CCN(CCCC(C3=CC=C(F)C=C3)=O)CC2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 1 year -20°C 6 months
Publications (22)
-
Journal Impact Factor
-
Most Recent
-
Cell
2023 Nov 22;186(24):5347-5362.e24. PMID: 37963465 -
Adv Sci (Weinh)
Dopamine D1 Receptor Contributes to Glucocorticoid-Associated Osteonecrosis of Femoral Head Protection Through the ATF3/CHOP Axis to Inhibit Osteoblastic Apoptosis. [Abstract]2025 Sep;12(33):e02276. PMID: 40583147
Haloperidol purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Sep;12(33):e02276. [Abstract]
Western blotting of DRD1, ALP, OCN, BAX, Bcl2, cleaved‐caspase3, and β‐actin in osteogenesis‐induced BMSCs treated with Haloperidol (1 µM), DA and then stimulated with MP.
-
Environ Sci Technol
2-Ethylhexyl Diphenyl Phosphate Causes Obesity in Zebrafish by Stimulating Overeating via Inhibition of Dopamine Receptor D2. [Abstract]2023 Sep 26;57(38):14162-14172. PMID: 37704188 -
Acta Biomater
Carrier-free spherical nucleic acids engineered by coordination-competition for programmable release and cancer immunotherapy. [Abstract]2026 Jun:216:333-347. PMID: 41962730 -
Phytomedicine
Valproic acid promotes transcriptional activation of Drd2 by mediating histone acetylation to inhibit the mTOR-Pttg1 signaling axis and exerts anti-PitNETs activity. [Abstract]2025 Jun:141:156707. PMID: 40220407 -
Br J Pharmacol
Exploiting D2 receptor β-arrestin2-biased signalling to suppress tumour growth of pituitary adenomas. [Abstract]2021 Sep;178(17):3570-3586. PMID: 33904172 -
Oncogenesis
Peroxisomal lipid metabolism inhibits Pimozide-induced cancer cell death by regulating ATP homeostasis. [Abstract]2025 Aug 21;14(1):31. PMID: 40841534 -
EMBO Rep
ZFP207 sustains pluripotency by coordinating OCT4 stability, alternative splicing and RNA export. [Abstract]2022 Feb 3;23(3):e53191. PMID: 35037361 -
J Ethnopharmacol
Total barley maiya alkaloids inhibit prolactin secretion by acting on dopamine D2 receptor and protein kinase A targets. [Abstract]2021 Jun 12:273:113994. PMID: 33711439 -
Eur J Pharmacol
A novel dopamine D2 receptor-NR2B protein complex might contribute to morphine use disorders. [Abstract]2023 Dec 15:961:176174. PMID: 37939993 -
Eur J Pharmacol
Sigma-1 receptor agonist properties that mediate the fast-onset antidepressant effect of hypidone hydrochloride (YL-0919). [Abstract]2023 May 5:946:175647. PMID: 36898424 -
Cell Rep Methods
RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]2023 Oct 23;3(10):100599. PMID: 37797618 -
ACS Omega
2025 Oct 17;10(42):50208-50217. PMID: 41179162
Haloperidol purchased from MedChemExpress. Usage Cited in: ACS Omega. 2025 Oct 17;10(42):50208-50217. [Abstract]
Haloperidol (Halo; 20 ng/mL; 24 h). ISR induction by various drugs. N2a cells were treated with the indicated drugs for 24 h. The cell extracts were analyzed by Western blot analysis with anti-ATF4, anti-CHOP, and anti-β actin antibodies.
-
ACS Omega
Computational Approaches to Identify Molecules Binding to Mycobacterium tuberculosis KasA. [Abstract]2020 Nov 15;5(46):29935-29942. PMID: 33251429 -
PLoS Negl Trop Dis
Identification of anti-flaviviral drugs with mosquitocidal and anti-Zika virus activity in Aedes aegypti. [Abstract]2019 Aug 20;13(8):e0007681. PMID: 31430351 -
BMC Endocr Disord
The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas. [Abstract]2021 Nov 23;21(1):235. PMID: 34814904 -
Clin Exp Pharmacol Physiol
Dopamine receptor D2 inhibition alleviates diabetic hepatic stellate cells fibrosis by regulating the TGF-β1/Smads and NFκB pathways. [Abstract]2021 Mar;48(3):370-380. PMID: 33179312
Haloperidol purchased from MedChemExpress. Usage Cited in: Clin Exp Pharmacol Physiol. 2021 Mar;48(3):370-380. [Abstract]
Haloperidol (10 μM; 48 h). Cell viability was measured by CCK-8 assay. The cells incubated with control medium were considered 100% viable.
Haloperidol purchased from MedChemExpress. Usage Cited in: Clin Exp Pharmacol Physiol. 2021 Mar;48(3):370-380. [Abstract]
Haloperidol (10 μM; 48 h). ROS production in HSCs measured by staining with DCFH-DA and imaged by fluorescent microscopy.
Haloperidol purchased from MedChemExpress. Usage Cited in: Clin Exp Pharmacol Physiol. 2021 Mar;48(3):370-380. [Abstract]
Haloperidol (10 μM; 48 h). Immunoblotting and optical density analysis of DRD2 and NOX-5, and the data were normalized to GAPDH.
-
Behav Brain Res
Activation of dopamine D2 receptors in the shell of nucleus accumbens triggers conditioned avoidance responses in rats. [Abstract]2022 Mar 26:422:113759. PMID: 35051488 -
-
-
-
Solvent & Solubility
DMSO : 40 mg/mL (106.42 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.67 mg/mL (4.44 mM); Clear solution
This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 1.67 mg/mL (4.44 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 1.67 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
Male albino mice of Swiss-Webster strain (33-36 g) are used, and all substances are given by i.p. injection in a volume of 0.5 mL. CPZ, haloperidoi and mescaline are all in time form of timeir imydrochlorides and the dose solutions are prepared at concentrations of 1.0, 0.66 and 3.3 mg/mL of 0.9% saline, respectively. The doses are: CPZ, 15 mg/kg; haloperidol, 10 mg/kg; mescaline, 50 mg/kg. Mice are pretreated with either CPZ or haloperidol 30 minutes before administration of mescaline. In some instances CPZ is injected 45 minutes after mescaline. Time animals are hmoused individually in a plexiglas cage and the gross behavior and locomotor activity. At selected intervals after mescaline, groups of mice are sacrificed by decapitation. Plasma is separated and stored at -20°C. The brain, liver, kidney, lung, spleen and heart are frozen on dry ice and stored at -20°C for 18 to 20 hours before they are used for assays.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (644 KB)
- English - EN (644 KB)
- Français - FR (644 KB)
- Deutsch - DE (644 KB)
- Norwegian - NO (644 KB)
- Español - ES (644 KB)
- Swedish - SV (644 KB)
- Italian - IT (644 KB)
- Korean - KR (644 KB)
- Portuguese - PT (644 KB)
-
Handling Instructions (2659 KB)
References
[1]. Furuta Y, et al. Effects of enzyme inhibitors of catecholamine metabolism and of haloperidol on the pancreatic secretion induced by L-DOPA and by dopamine in dogs. Br J Pharmacol. 1973 Jan;47(1):77-84 [Content Brief]
[2]. Shah NS, et al. Effects of chlorpromazine and haloperidol on the disposition of mescaline-14C in mice. J Pharmacol Exp Ther. 1973 Aug;186(2):297-304 [Content Brief]
[3]. Lei K, et al. Investigation of the synergistic effects of haloperidol combined with Calculus Bovis Sativus in treating MK-801-induced schizophrenia in rats. Exp Anim. 2018 May 10;67(2):163-173. [Content Brief]
[4]. Guzen FP, et al. Haloperidol-Induced Preclinical Tardive Dyskinesia Model in Rats. Curr Protoc Neurosci. 2019 Jun;88(1):e68. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6606 mL | 13.3028 mL | 26.6057 mL | 66.5141 mL |
| 5 mM | 0.5321 mL | 2.6606 mL | 5.3211 mL | 13.3028 mL | |
| 10 mM | 0.2661 mL | 1.3303 mL | 2.6606 mL | 6.6514 mL | |
| 15 mM | 0.1774 mL | 0.8869 mL | 1.7737 mL | 4.4343 mL | |
| 20 mM | 0.1330 mL | 0.6651 mL | 1.3303 mL | 3.3257 mL | |
| 25 mM | 0.1064 mL | 0.5321 mL | 1.0642 mL | 2.6606 mL | |
| 30 mM | 0.0887 mL | 0.4434 mL | 0.8869 mL | 2.2171 mL | |
| 40 mM | 0.0665 mL | 0.3326 mL | 0.6651 mL | 1.6629 mL | |
| 50 mM | 0.0532 mL | 0.2661 mL | 0.5321 mL | 1.3303 mL | |
| 60 mM | 0.0443 mL | 0.2217 mL | 0.4434 mL | 1.1086 mL | |
| 80 mM | 0.0333 mL | 0.1663 mL | 0.3326 mL | 0.8314 mL | |
| 100 mM | 0.0266 mL | 0.1330 mL | 0.2661 mL | 0.6651 mL |